A startup developing treatments for eye diseases has raised $330 million from investors as it readies for late-stage testing.
Ollin Biosciences is about to begin a Phase 3 trial of a treatment for both diabetic macular edema and wet age-related macular degeneration. The conditions affect millions of Americans and can lead to vision loss.
Ahead of the trial, Ollin told STAT it had raised the Series B funding from an assortment of established biotech investors, a pension fund, and even crossover investors — a breed of private investors who will take a stake in a company shortly before it moves over to the stock market. TCGX and ARCH Venture Partners co-led the funding round, which was one of the largest Series B rounds for a biotech company in the last two years.
Continue to STAT+ to read the full story…
— Source: STAT News (https://www.statnews.com/2026/06/24/ophthalmology-biotech-ollin-biosciences/)
